Get the Latest Investment Ideas Delivered Straight to Your Inbox.

News Update

TICKERS: VIV

Developer of Premix for Livestock Feed Lands Sizable Order from Asia
News Update

Source:

Demand for the Canadian company's product is growing in the Asia-Pacific region.

Avivagen Inc. (VIV:TSX.V) announced in a news release it received another order for two metric tons of its product, OxC-beta Livestock, from UNAHCO, its partner and a feed manufacturer in the Philippines. This is UNAHCO's third such order in the past 10 months.

"The Asia-Pacific market represents a significant growth region for Avivagen and OxC-beta Livestock," Avivagen CEO Kym Anthony said in the release. "This third substantial order by UNAHCO in the past year shows the steadily increasing demand and recurring revenue experienced in the region."

The company noted that "OxC-beta™ Livestock has the potential to eliminate the use of antibiotics as growth promoters in livestock feed, a problem requiring an urgent solution and which represents a multi-million-dollar market opportunity worldwide."

The Asia-Pacific region produces nearly 400 million metric tons of feed each year, which constitutes more than one-third of the metric ton global feed market. Avivagen expects uptake of OxC-beta to increase as the company seeks regulatory approvals in additional jurisdictions.

The company recently received approval to sell OxC-beta Livestock for "certain applications in Mexico and became eligible to sell OxC-beta Livestock in the United States."

[NLINSERT]

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Avivagen. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.




Want to read more about Nutraceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe